Latest News for: delcath

Edit

Delcath Systems to Host First Quarter 2026 Earnings Call

Business Wire 23 Apr 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq ... Event Date. Thursday, May 7, 2026 Time .
Edit

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended ...

Business Wire 06 Apr 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq ... M-PHP is also re .
Edit

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma (Delcath Systems Inc)

Public Technologies 06 Apr 2026
6, 2026-- Delcath Systems, Inc ... About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT. Delcath Systems, Inc ... HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS) ... Delcath Systems, Inc.
Edit

Additional Proxy Soliciting Materials (Form DEFA14A) (Delcath Systems Inc)

Public Technologies 02 Apr 2026
). UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, DC 20549. _____________________. SCHEDULE 14A. (Rule 14a-101). INFORMATION REQUIRED IN PROXY STATEMENT. SCHEDULE 14A INFORMATION ... _____________________ ... Delcath Systems, Inc ... Delcath Systems Inc.
Edit

Annual Report (Form ARS) (Delcath Systems Inc)

Public Technologies 02 Apr 2026
). The text version of this document is not available ... Delcath Systems Inc.
Edit

Proxy Statement (Form DEF 14A) (Delcath Systems Inc)

Public Technologies 02 Apr 2026
Delcath Systems, Inc ... To the Stockholders of Delcath Systems, Inc... Notice is hereby given that the 2026 Annual Meeting of Stockholders of Delcath Systems, Inc., a Delaware corporation (the "Company"), will be held virtually at 10.00 a.m.
Edit

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Business Wire 01 Apr 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc ... At the event, Delcath’s Hepatic Delivery ...
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Delcath Systems Inc)

Public Technologies 06 Mar 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... OMB Number ... DELCATH SYSTEMS, INC ... C/O DELCATH SYSTEMS, INC., 566 QUEENSBURY AVENUE 3 ... C/O DELCATH SYSTEMS, INC ... Delcath Systems Inc.
Edit

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Business Wire 03 Mar 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc ... DCTH), (“Delcath” or the “Company”) an ...
Edit

CHOPIN Clinical Trial Results in The Lancet Oncology (Form 8-K) (Delcath Systems Inc)

Public Technologies 03 Mar 2026
QUEENSBURY, NY - March 3, 2026 Delcath Systems, Inc ... About Delcath Systems, Inc., HEPZATO KIT, and CHEMOSAT. Delcath Systems, Inc ... HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary HDS ... Delcath Systems Inc.
Edit

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Business Wire 26 Feb 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc ... DCTH) (“Delcath” or the “Company”), an ...
Edit

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results (Form 8-K) (Delcath Systems Inc)

Public Technologies 26 Feb 2026
) Delcath Systems Reports Fourth Quarter and ... QUEENSBURY, NY - February 26, 2026, Delcath Systems, Inc ... Delcath has provided in this release certain financial information that has not been prepared in accordance with GAAP ... Delcath Systems, Inc.
Edit

Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) (Delcath Systems Inc)

Public Technologies 26 Feb 2026
) Management's Discussion and Analysis of Financial Condition and Results of Operations ... Overview. We are an interventional oncology company focused on the treatment of cancers primary or metastatic to the liver ... The FOCUS Trial ... Delcath Systems Inc.
Edit

Ocular melanoma Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Delcath System, ...

GetNews 19 Feb 2026
The Key Ocular melanoma Companies in the market include - Immunocore, Delcath Systems, IDEAYA Biosciences, Aura Biosciences, Linnaeus Therapeutics, Turnstone Biologics, Seagen, IDEAYA, Ascentage Pharma, and others ... Delcath Systems ... Delcath System.
Edit

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Business Wire 12 Feb 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq ... Event Date. Th .

Article Search

tools
×
×
×
×